Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
letter
. 2026 Jul 29;108(2):e70891. doi: 10.1111/tan.70891

Six Novel HLA‐DQB1*05 Intronic Variants Identified by Next‐Generation Sequencing

Luis Alberto Marin Rubio 1,✉, Jesus Ontañon 1
PMCID: PMC13416813  PMID: 42522466

ABSTRACT

Genomic sequences of the intronic variants HLA‐DQB1*05:01:01:35, ‐DQB1*05:01:01:36, ‐DQB1*05:01:01:41, ‐DQB1*05:02:01:20, ‐DQB1*05:03:01:11 and ‐DQB1*05:03:01:13.

Keywords: HLA‐DQB1*05, new alleles, next‐generation sequencing


We report the identification of the six novel intronic variants HLA‐DQB1*05:01:01:35, ‐DQB1*05:01:01:36, ‐DQB1*05:01:01:41, ‐DQB1*05:02:01:20, ‐DQB1*05:03:01:11 and ‐DQB1*05:03:01:13 characterised during routine typing for HLA Class I (HLA‐A, ‐B and ‐C) and Class II (HLA‐DRB1, ‐DQA1, ‐DQB1, ‐DPA1 and ‐DPB1) of potential bone marrow donors by next‐generation sequencing (NGS).

Peripheral blood genomic DNA was extracted using Maxwell Blood DNA Purification System (Promega Corporation, Madison, USA) according to the manufacturer's instructions. HLA typing for HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQA1, ‐DQB1, ‐DPA1 and ‐DPB1 loci was performed using commercial NGSgo‐MX11‐3 kits (GenDx, Utrecht, The Netherlands). The sequencing was performed on a MiniSeq system (Illumina, San Diego, California) and was analysed with NGSengine software V2.31 to V4.0 (GenDx) and IPD‐IMGT/HLA Database versions 3.53.0 to 3.60.0 [1].

Characteristics of the novel alleles and their most similar variants in the IPD‐IMGT/HLA Database are shown in Table 1.

TABLE 1.

Characteristics of the new HLA‐DQB1*05 alleles.

Novel allele Most similar allele gDNA position change GenBank accession number IPD‐IMGT/HLA submission number Genotype of the individual with novel allele
DQB1*05:01:01:35 DQB1*05:01:01:01

809‐812delACTG

Intron 1

PP309834 HWS10069483 A*29:02:01:01, 33:01:01:01; C*08:02:01, 16:01:01:01; B*14:02:01:01, 44:03:01; DRB4*01:01:01:01; DRB1*01:02:01, 07:01:01; DQA1*01:02:01, 02:01:01; DQB1*02:02:01:01, 05:01:01:35; DPA1*01:03:01, 02:01:01:01; DPB1*02:01P, 11:01:01
DQB1*05:01:01:36 DQB1*05:01:01:03

6184 G>A

Intron 5

PP468608 HWS10069903 A*02:01:01, 23:01:01:01; C*05:01:01, 15:05:02; B*07:06:01:01, 44:02:01; DRB3*02:02:01; DRB1*01:03:01:01, 11:04P; DQA1*01:01:01, 05:05:01; DQB1*03:01:01, 05:01:01:36; DPA1*01:03:01, 01:03:01; DPB1*04:01P, 04:01P
DQB1*05:01:01:41 DQB1*05:01:01:03

2283 T>C

Intron 2

PV241190 HWS10100619 A*01:01:01, 30:02:01:01; C*07:01:01, 15:02:01; B*08:01:01, 51:01:01; DRB5*01:01:01; DRB1*01:01P, 15:01:01; DQA1*01:01:01, 01:02:01; DQB1*05:01:01:41, 06:02:01; DPA1*01:03:01:04, 02:01:02:02; DPB1*01:01:01, 04:01:01
DQB1*05:02:01:20 DQB1*05:02:01:01

3695 G>T

Intron 2

PP993593 HWS10091205 A*24:02:01, 74:02:01:02; C*04:03:01, 07:04:01; B*15:25:01:01, 18:01:01; DRB3*03:01:03:02; DRB5*01:02:01; DRB1*12:02P, 16:02:01; DQA1*01:02:02:01, 06:01:01; DQB1*03:01:01:12, 05:02:01:20; DPA1*01:03:01, 02:02:02; DPB1*02:02:01, 03:01:01
DQB1*05:03:01:11 DQB1*05:03:01:01

5258 A>G

Intron 4

PP197925 HWS10069171 A*23:17:01:01, 26:01:01; C*07:02:01, 08:02:01:02; B*08:01:01, 14:01:01:01; DRB3*02:02P; DRB4*01:01:01:01; DRB1*07:01:01, 14:01P; DQA1*01:05:02, 02:01:01; DQB1*02:02:01:01, 05:03:01:11; DPA1*01:03:01:04, 01:03:01:04; DPB1*02:01P, 04:01P
DQB1*05:03:01:13 DQB1*05:03:01:04

2283 C>G

Intron 2

PX422483 HWS10102044 A*02:06:01, 33:03:01; C*08:01:01, 14:03:01:01; B*44:03:01, 48:01:01; DRB3*02:02P; DRB1*08:03, 14:01P; DQA1*01:03:01, 01:04:01; DQB1*05:03:01:13, 06:01:01:01; DPA1*01:03:01, 02:02:02; DPB1*04:02P, 05:01P

The names HLA‐DQB1*05:01:01:35, ‐DQB1*05:01:01:36, ‐DQB1*05:01:01:41, ‐DQB1*05:02:01:20, ‐DQB1*05:03:01:11 and ‐DQB1*05:03:01:13 have been officially assigned by the WHO Nomenclature Committee for Factors of the HLA System from February 2024 to December 2025. This follows the agreed policy that, subject to the conditions stated in the most recent Nomenclature Report [2], names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report.

Author Contributions

Luis Alberto Marin Rubio and Jesus Ontañon designed the study and data analysis. Luis Alberto Marin Rubio submitted the new alleles to IPD‐IMGT/HLA Database. Luis Alberto Marin Rubio wrote the manuscript. All authors read and approved the final version of the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  • 1. Barker D. J., Natarajan R. H. L., Cooper M. A., et al., “The IPD‐IMGT/HLA Database: Recent Developments in Sequence Submission,” Nucleic Acids Research 54 (2026): D1152–D1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Marsh S. G. E., Osoegawa K., Bodmer W. F., et al., “Nomenclature for Factors of the HLA System, 2026,” HLA 107 (2026): e70595. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Articles from Hla are provided here courtesy of Wiley

RESOURCES